KLK3 and posterior cortical atrophy: In clinical settings, the PHI is primarily used to improve individual risk assessments for early PCa detection [26] and reduce unnecessary biopsies in males with borderline PSA levels, resulting in reductions that range from approximately 15% to 45%, depending on the selected threshold [27].